Updates in the Treatment Paradigm for Multiple Myeloma
Posted: 07/13/2022 | By: Justine Landin, PhD

At the NCCN 2022 Annual Conference, Shaji K. Kumar, MD, Consultant, Division of Hematology, and the Mark and Judy Mullins Professor of Hematologic Malignancies, Mayo Clinic Cancer Center, as well as Chair of the NCCN Guidelines Panel for Multiple Myeloma, discussed the many new treatment options added to the armamentarium for multiple myeloma in the past few years.

Question 1 of 5

For transplant-eligible disease, which induction approach is suggested to be ideal?

Choose 1